(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/239928 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 9/10* (2006.01)

(21) International Application Number:
PCT/EP2021/064312

(22) International Filing Date:
28 May 2021 (28.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/031,854 29 May 2020 (29.05.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: **SINIBALDI, Dominic**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **WHITE, Wendy**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **SMITH, Michael**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **CASEY, Kerry**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **ILLEI, Gabor**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF CARDIOMETABOLIC DISEASE WITH INHIBITORS OF TYPE I INTERFERON SIGNALLING

(57) Abstract: The disclosure relates to methods for the treatment of, or for reducing the risk for development of, a cardiometabolic in a patient using an inhibitor of type I IFN signalling.

FIG. 1

BILAG-2004 INDEX Centre: Date: Initials/Hosp No:

♦ Only record manifestations/items due to SLE Disease Activity
♦ Assessment refers to manifestations occurring in the last 4 weeks (compared with the previous 4 weeks)
♦ TO BE USED WITH THE GLOSSARY

Record: NO Not Done
0 Not present
1 Improving
2 Same
3 Worse
4 New
Yes/No OR Value (where indicated)
♦Y/N Confirm this is due to SLE activity (Yes/No)

CONSTITUTIONAL
1. Pyrexia - documented > 37.8°C ( )
2. Weight loss - unintentional > 5% ( )
3. Lymphadenopathy/splenomegaly ( )
4. Anorexia ( )

MUCOCUTANEOUS
5. Skin eruption - severe ( )
6. Skin eruption - mild ( )
7. Angio-oedema - severe ( )
8. Angio-oedema - mild ( )
9. Mucosal ulceration - severe ( )
10. Mucosal ulceration - mild ( )
11. Panniculitis/Bullous lupus - severe ( )
12. Panniculitis/Bullous lupus - mild ( )
13. Major cutaneous vasculitis/Amyloidosis ( )
14. Digital infarcts or nailfold vasculitis ( )
15. Alopecia - severe ( )
16. Alopecia - mild ( )
17. Peri-ungual erythema/telangiectasia ( )
18. Salivary hypertrophy ( )

NEUROPSYCHIATRIC
19. Aseptic meningitis ( )
20. CVA/Non vasculitis ( )
21. Demyelinating syndrome ( )
22. Myelopathy ( )
23. Acute confusional state ( )
24. Psychosis ( )
25. Acute inflammatory demyelinating polyradiculoneuropathy ( )
26. Mononeuropathy (single/multiplex) ( )
27. Cranial neuropathy ( )
28. Polyneuropathy ( )
29. Polyneuropathy ( )
30. Seizure disorder ( )
31. Status epilepticus ( )
32. Cerebrovascular disease (not due to vasculitis) ( )
33. Cognitive dysfunction ( )
34. Movement disorder ( )
35. Autonomic disorder ( )
36. Cerebellar ataxia (isolated) ( )
37. Lupus headache - severe worsening ( )
38. Headache from IC hypertension ( )

MUSCULOSKELETAL
39. Myositis - severe ( )
40. Myositis - mild ( )
41. Arthritis (>2 joints) ( )
42. Arthritis (moderate)/Tendonitis/Enthesopathy ( )
43. Arthritis (mild)/Arthralgia/Myalgia ( )

Weight (kg): Serum urea (mmol/l):
African ancestry: Yes/No Serum albumin (g/l):

CARDIORESPIRATORY
44. Myocarditis - mild ( )
45. Myocarditis/Endocarditis ± Cardiac failure ( )
46. Antiphospholipid syndrome ( )
47. New valvular dysfunction ( )
48. Pleurisy/Pericarditis ( )
49. Cardiac tamponade ( )
50. Pleural effusion with dyspnoea ( )
51. Pulmonary haemorrhage/ Alveolitis ( )
52. Interstitial fibrosis/pneumonitis ( )
53. Shrinking lung syndrome ( )
54. Arthritis ( )
55. Coronary vasculitis ( )

GASTROINTESTINAL
56. Lupus peritonitis ( )
57. Abdominal serositis or ascites ( )
58. Lupus enteritis/colitis ( )
59. Malabsorption ( )
60. Protein losing enteropathy ( )
61. Intestinal pseudo-obstruction ( )
62. Lupus hepatitis ( )
63. Acute hepatic cholecystitis ( )
64. Acute lupus pancreatitis ( )

OPHTHALMIC
65. Orbital inflammation/uveitis/episcleritis/proptosis ( )
66. Keratitis - severe ( )
67. Keratitis - mild ( )
68. Retinitis/cytitis ( )
69. Posterior ischaemic/retinal vasculitis - severe ( )
70. Posterior ischaemic/retinal vasculitis - mild ( )
71. Episcleritis ( )
72. Scleritis - severe ( )
73. Scleritis - mild ( )
74. Retinal/choroidal vaso-occlusive disease ( )
75. Isolated cotton-wool spots (cytoid bodies) ( )
76. Optic neuritis ( )
77. Anterior ischaemic optic neuropathy ( )

RENAL
78. Systolic blood pressure (mm Hg) value ( ) Y/N+
79. Diastolic blood pressure (mm Hg) value ( ) Y/N+
80. Accelerated hypertension Yes/No ( )
81. Urine dipstick protein (+=1, ++=2, +++=3) ( ) Y/N+
82. Urine albumin-creatinine ratio mg/mmol ( ) Y/N+
83. Urine protein-creatinine ratio mg/mmol ( ) Y/N+
84. 24 hour urine protein (g) value ( ) Y/N+
85. Nephrotic syndrome Yes/No ( )
86. Glomerulonephritis/Lupus nephritis ( ) Y/N+
87. GFR (calculated) ml/min/1.73 m² ( ) Y/N+
88. Active urinary sediment Yes/No ( )
89. Active nephritis Yes/No ( )

HAEMATOLOGICAL
90. Haemoglobin (g/l) value ( ) Y/N+
91. Total white cell count (x 10⁹/l) value ( ) Y/N+
92. Neutrophils (x 10⁹/l) value ( ) Y/N+
93. Lymphocytes (x 10⁹/l) value ( ) Y/N+
94. Platelets (x 10⁹/l) value ( ) Y/N+
95. TTP ( )
96. Evidence of active haemolysis Yes/No ( )
97. Coombs' test positive (isolated) Yes/No ( )

[Continued on next page]

WO 2021/239928 A3

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

27 January 2022 (27.01.2022)